Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Xin-Ye Wang, Yu-Jue Wang, Zi-Lin Hou, Bo-Wen Guo, Ru-Qi Wang, Qingbo Liu, Guo-Dong Yao & Shao-Jiang Song. (2023) Ingenane-type diterpenoids inhibit non-small cell lung cancer cells by regulating SRC/PI3K/Akt pathway. Natural Product Research 0:0, pages 1-6.
Read now
Read now
Articles from other publishers (7)
Emily J. Hanan, Marie-Gabrielle Braun, Robert A. Heald, Calum MacLeodConnie Chan, Saundra Clausen, Kyle A. Edgar, Charles Eigenbrot, Richard ElliottNicholas Endres, Lori S. Friedman, Emily Gogol, Xiao-Hui Gu, Rebecca Hong Thibodeau, Philip S. JacksonJames R. Kiefer, Jamie D. KnightMichelle Nannini, Raman NarukullaAmanda Pace, Jodie Pang, Hans E. Purkey, Laurent Salphati, Deepak Sampath, Stephen Schmidt, Steve Sideris, Kyung Song, Swathi Sujatha-Bhaskar, Mark Ultsch, Heidi Wallweber, Jianfeng Xin, SiewKuen YeapAmy Young, Yu Zhong & Steven T. Staben. (2022) Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα. Journal of Medicinal Chemistry 65:24, pages 16589-16621.
Crossref
Crossref
Amandeep Thakur, Chetna Faujdar, Ram Sharma, Sachin Sharma, Basant Malik, Kunal Nepali & Jing Ping Liou. (2022) Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry 65:13, pages 8596-8685.
Crossref
Crossref
Yixuan Ma, Sina Sender, Anett Sekora, Weibo Kong, Peter Bauer, Najim Ameziane, Ruslan Al-Ali, Susann Krake, Mandy Radefeldt, Frank Ulrich Weiss, Markus M. Lerch, Alisha Parveen, Dietmar Zechner, Christian Junghanss & Hugo Murua Escobar. (2022) The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences 23:8, pages 4295.
Crossref
Crossref
Shuo Deng, Hin Chong Leong, Arpita Datta, Vennila Gopal, Alan Prem Kumar & Celestial T. Yap. (2022) PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. Cancers 14:7, pages 1652.
Crossref
Crossref
Nicola Fusco, Umberto Malapelle, Matteo Fassan, Caterina Marchiò, Simonetta Buglioni, Simonetta Zupo, Carmen Criscitiello, Paolo Vigneri, Angelo Paolo Dei Tos, Eugenio Maiorano & Giuseppe Viale. (2021) PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Xin-Yu Liu & Lizi Zhang. (2021) Oridonin, an AKT1 Inhibitor, Suppresses the Growth of Breast Cancers with Hyperactivation of PI3K/AKT Signaling. E3S Web of Conferences 271, pages 03014.
Crossref
Crossref
Allison N. DuRoss, Megan J. Neufeld, Madeleine R. Landry, Justin G. Rosch, Colin T. Eaton, Gaurav Sahay, Charles R. ThomasJr.Jr. & Conroy Sun. (2019) Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy. ACS Applied Materials & Interfaces 11:13, pages 12342-12356.
Crossref
Crossref